$NTRR Forges Ahead

Neutra Corp. (NTRR) announced plans today to forge ahead with the marketing and development of a new inhaler containing an all-natural, libido-boosting supplement as an alternative to populartestosterone drugs the FDA says increase the risk of heart attack and stroke.

A CBS outlet reported last week that nearly three percent of men over 40 take testosterone drugs for low energy and libido, fueling a $2 billion market in the U.S. But the FDA issued a statement last week saying that overuse of testosterone drugs is unsafe for those with age-related diseases, and are not to be used to counteract the normal effects of aging. NTRR is working to develop a novel new alternative to testosterone drugs that uses an all-natural and effective herbal supplement, eliminating the risks and barriers associated with prescriptions.

“Testosterone boosters, which are intended to be used only by a select group of men diagnosed with low testosterone by their doctors, are a risky and often ineffective solution to the loss of libido,” said NTRR CEO Chris Brown. “We’re now seeking development partners for a cutting-edge new inhaler that will boost libido quickly, naturally and inconspicuously, without the risk factors described by the FDA in testosterone drugs.”

As vapor pens and e-cigs become a lifestyle accessory around the globe, NTRR believes that disposable inhaler technology is poised to become a new and better industry standard for a wide variety of supplements and nutraceuticals—including those developed to improve sexual function and desire in men. The company’s research indicates that a libido-boosting inhaler will be more effective and faster-acting than pills and other supplements on the market, and NTRR plans to be the first to offer such a product.

The new technology is one of several products that the company is developing to diversify its offerings and expand its earnings potential in the global nutraceuticals market.